Actuate Restructures Offering: 40M Shares + 20M Warrants at $1.00 Combined, Adds Two-Year Insider Lock-Ups
ACTU sits 42% above its 52-week low of $0.41 on elevated volume (2.7× avg).
Summary
Actuate refiled its public offering on restructured terms: 40 million shares plus 20 million warrants at an assumed $1.00 per two shares, with up to 40 million pre-funded warrants and two-year lock-ups from its two largest holders. The raise is deeply dilutive but funds a company that had only $4.4 million of cash and going-concern doubt.
Key Events · Financing and Capital Events · ACTU
-
Offering Restructured and Downsized
40,000,000 shares plus 20,000,000 five-year purchase warrants at an assumed combined price of $1.00 per two shares (effective $0.50 per share), replacing the prior 65,000,000-share structure at $0.6437.
-
Severe Dilution to Existing Holders
40 million new shares versus 24,013,577 outstanding as of June 30, 2026 — roughly 1.7x the current base before any of the 20 million purchase warrants or 40 million pre-funded warrants are exercised.
-
Insider Lock-Ups Bought With Warrants
Bios Entities and Kairos Entities, holding about 50% of shares, agreed to two-year lock-ups and receive 3,000,000 and 700,000 warrants respectively at 150% of the offering price; other officers and directors lock up for 120 days.
-
Cash Position and Going-Concern Risk
Company had $4,425,841 of cash and $942,745 of working capital at June 30, 2026, and states substantial doubt about its ability to continue as a going concern absent new financing; proceeds are earmarked for working capital and general corporate purposes.
Analysis · ACTU · Life Sciences
Actuate is pressing ahead with a survival-level raise on renegotiated terms. The deal now sells 40 million shares bundled with 20 million five-year warrants at an assumed $1.00 per two shares — an effective $0.50 per share, matching the October 15 last reported sale price — plus up to 40 million pre-funded warrants for buyers hitting ownership caps. That is roughly 1.7x the 24.0 million shares outstanding as of June 30, 2026, before counting any warrant exercise, so existing holders face severe dilution. The company had $4.4 million of cash and $0.9 million of working capital at June 30, 2026, and its own risk factors flag substantial doubt about going concern, so this capital is oxygen rather than growth funding. In exchange for two-year lock-ups from Bios and Kairos — holders of roughly half the shares — those insiders receive 3.7 million warrants struck at 150% of the offering price, aligning the largest holders with the outcome but also concentrating the economics. The Nasdaq minimum market value shortfall (notice received July 15, 2026, compliance deadline January 11, 2027) adds urgency: a completed raise helps the market-value test, but the sub-$1 share price keeps the separate minimum bid requirement in play.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 43.2% of the 271 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.30%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACTU was trading at $0.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.5M. The 52-week trading range was $0.41 to $8.20. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.